Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019
- PMID: 38852942
- DOI: 10.1080/09546634.2024.2360568
Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019
Abstract
Background: Response rates of approved systemic therapies for cutaneous T-cell lymphoma (CTCL) hover near 30%, suggesting unmet need. This study describes real-world treatment patterns and response rates of extracorporeal photopheresis (ECP) in CTCL patients.
Methods: A chart review was conducted in the United States of adults with CTCL who initiated ECP between January 1, 2017, and February 28, 2019, and received at least three months of ECP treatment as monotherapy or concomitant therapy. Clinical outcomes were collected quarterly for up to 18 months.
Results: The 52 patients were predominantly Caucasian. Half were male; median age was 69 years. Most patients had Sézary syndrome (50%) or mycosis fungoides (36.5%). Nearly 40% of patients had stage IV disease; 33% had lymph node involvement. Nineteen patients (36.5%) achieved response (>50% reduction in BSA affected); median time to response was 6.5 months. The percentage of patients rated as at least minimally improved was 59.5% at 6 months (N = 22), 75.0% at 9 months (N = 24), and 60.0% at 12 months (N = 15) after ECP initiation.
Conclusions: Despite the ECP treated population in this study being older and having more advanced-stage disease than recent trials, response rates were comparable. These real-world findings support ECP as an effective treatment option for CTCL patients.
Keywords: Lymphoma; T-Cell; observational study; photopheresis; real-world data.
Similar articles
-
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.J Am Acad Dermatol. 2014 Feb;70(2):223.e1-17; quiz 240-2. doi: 10.1016/j.jaad.2013.08.033. J Am Acad Dermatol. 2014. PMID: 24438970 Review.
-
What Does the Future Hold for Biomarkers of Response to Extracorporeal Photopheresis for Mycosis Fungoides and Sézary Syndrome?Cells. 2023 Sep 20;12(18):2321. doi: 10.3390/cells12182321. Cells. 2023. PMID: 37759543 Free PMC article. Review.
-
Extracorporeal photopheresis and multimodality therapy in patients with T-cell cutaneous lymphomas: Real-life experience in Argentina.J Clin Apher. 2021 Dec;36(6):815-822. doi: 10.1002/jca.21933. Epub 2021 Sep 3. J Clin Apher. 2021. PMID: 34478581
-
Extracorporeal photophoresis: an evidence-based analysis.Ont Health Technol Assess Ser. 2006;6(6):1-82. Epub 2006 Mar 1. Ont Health Technol Assess Ser. 2006. PMID: 23074497 Free PMC article.
-
Predictors of response to extracorporeal photopheresis in advanced mycosis fungoides and Sézary syndrome.Photodermatol Photoimmunol Photomed. 2010 Aug;26(4):182-91. doi: 10.1111/j.1600-0781.2010.00514.x. Photodermatol Photoimmunol Photomed. 2010. PMID: 20626820 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical